Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease

INTRODUCTION: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy was approved by the United States Food and Drug Administration in 2017 as a maintenance therapy for chronic obstructive pulmonary disease (COPD). Patient characteristics and treatment patterns prior...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Benjamin, Mannino, David, Mu, George, Stiegler, Marjorie, Bogart, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098773/
https://www.ncbi.nlm.nih.gov/pubmed/35467260
http://dx.doi.org/10.1007/s41030-022-00189-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098773/
https://www.ncbi.nlm.nih.gov/pubmed/35467260
http://dx.doi.org/10.1007/s41030-022-00189-6

Ejemplares similares